Stephen Oesterle

Steve has worked on VC and PE investments as a venture partner or advisor with New Enterprise Associates, EQT Partners, Temasek, and Cathay Capital. Previously, Steve served as Medtronic’s Senior Vice President for Medicine and Technology and was a member of the Medtronic Executive Committee for 14 years. By forging relationships with global technology partners and technical universities, he oversaw long-term internal technology investments while participating in strategic corporate investments in emerging private companies. He also served as a member of the Business Development and Strategy Committee that approved all corporate acquisitions. During his tenure at Medtronic Steve served on more than 20 boards as a director or observer and built a strong and enduring profile for Medtronic in the global venture capital and private equity communities.

Along with Paragon 28, Steve currently serves on the public boards of Baxter (NYSE: BAX), Sigilon Therapeutics (NASDAQ. SGTX), and Shanghai cardiovascular device company Peijia Medical (HKG: 9996). He also serves as an independent director on private equity-backed companies – CeramTec (BC Capital and CPPIB owned), a global leader in ceramic medical and industrial products, and SHL Medical AG (EQT Partners), a market leader in auto-injectors for biologics and VC backed companies, Alcyone Therapeutics - developing targeted gene therapies for the central nervous system, and Anunica, a medical device company treating hydrocephalus. He is also on the advisory boards of Alphabet’s Verily, and Rainbow Medical, an Israeli device incubator.